Clinical Infectious Diseases Advance Access published June 8, 2015

Clinical Infectious Diseases Advance Access published June 8, 2015 MAJOR ARTICLE HIV/AIDS Extended-Release Niacin Versus Fenofibrate in HIV-Infected...
Author: Jemima Lewis
1 downloads 0 Views 304KB Size
Clinical Infectious Diseases Advance Access published June 8, 2015

MAJOR ARTICLE

HIV/AIDS

Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low HighDensity Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation Michael P. Dubé,1 Lauren Komarow,2 Carl J. Fichtenbaum,3 Joseph J. Cadden,1 Edgar T. Overton,4 Howard N. Hodis,1 Judith S. Currier,5 and James H. Stein6; for the AIDS Clinical Trials Group A5293 Study Team 1

University of Southern California Keck School of Medicine, Los Angeles; 2Harvard School of Public Health, Boston, Massachusetts; 3University of Cincinnati, Ohio; 4University of Alabama at Birmingham; 5University of California at Los Angeles; and 6University of Wisconsin School of Medicine and Public Health, Madison

Background. Low levels of high-density lipoprotein cholesterol (HDL-C) are common in individuals with human immunodeficiency virus (HIV) infection, persist during antiretroviral therapy (ART), and are associated with increased cardiovascular disease (CVD) risk. Methods. Virologically controlled participants without CVD on stable ART with low HDL-C (men

Suggest Documents